Moderna continues to cut costs, which could raise questions about the vaccine playbook used during the Covid-19 pandemic.

Moderna said on Monday it achieved $3 billion to $3.1 billion in product sales in 2024, and reduced cash operating costs by ...

TUESDAY, Jan. 21, 2025 (HealthDay News) -- The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.

Pharmacist Kim Nguyen administers a Moderna Spikevax COVID-19 vaccine at a CVS, Wednesday, Sept. 20, 2023, in Cypress, Texas. Weak adoption of Moderna’s respiratory syncytial virus (RSV ...

The Cambridge-based company said it expects 2025 revenue of between $1.5 billion to $2.5 billion, down from its previous projection of between $2.5 billion and $3.5 billion.

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...

Erica Denhoff / Icon Sportswire via Getty Images Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech ...

Moderna is recruiting adult participants for Nova 301, its Phase 3 clinical trial evaluating an investigational norovirus vaccine called mRNA-1403.